Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05456880 · ClinicalTrials.gov registry record · Phase 1
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
A Phase 1 study of Sickle Cell Disease, sponsored by Beam Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 19
- Study locations
NCT05456880: Active Phase 1 study of Sickle Cell Disease, sponsored by Beam Therapeutics.
NCT05456880 is a Phase 1 study of Sickle Cell Disease that is active but no longer recruiting, run by Beam Therapeutics. The registered enrollment target is 15 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (95% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05456880, a Phase 1 study of Sickle Cell Disease, is active but no longer recruiting, sponsored by Beam Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Conditions Studied
Interventions
- BIOLOGICAL BEAM-101
Study Locations (19)
Florida
- Mayo Clinic Florida - Jacksonville
- University of Miami - Miami
New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Cleveland Clinic Foundation - Cleveland
Tennessee
- St Jude Children's Research Hospital - Memphis
- The Children's Hospital at TriStar Centennial - Nashville
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Georgia
- Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center - Egleston Hospital - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
What the registry record for NCT05456880 still lists
NCT05456880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which BEAM-101 is the first listed.
NCT05456880 lists 19 locations in 15 states (Florida, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT05456880 about?
NCT05456880 is a clinical study titled "BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease". This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
What is the current status of trial NCT05456880?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-08-30. Estimated completion is 2028-02.
What conditions does trial NCT05456880 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT05456880?
The interventions under investigation include: BEAM-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05456880?
This trial is sponsored by Beam Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05456880 being conducted?
This trial has 19 study locations across Alabama, Arizona, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05456880's enrollment target sits among peer trials
15 185th of 213 higher than 24 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
RECRUITING · Phase 1
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI